Drugs & Aging

, Volume 27, Issue 8, pp 625–640 | Cite as

Pharmacological and Clinical Profile of Newer Antidepressants

Implications for the Treatment of Elderly Patients
Review Article

Abstract

The pharmacological treatment of older adults with major depressive disorder presents a variety of challenges, including a relative lack of high quality studies designed to measure the efficacy and safety of antidepressants specific to this patient population. Gaining a clear understanding of how to use antidepressants in elderly patients with depression, especially new and widely used agents, would provide valuable insight to clinicians. The purpose of the current article is to review the pharmacology, efficacy and safety of newer antidepressants (i.e. escitalopram, duloxetine and desvenlafaxine) in the treatment of late-life depression. To accomplish this goal, a MEDLINE and PubMed search (1966 — February 2010) was conducted for relevant articles. Animal and human studies have clearly demonstrated the effects of desvenlafaxine, duloxetine and escitalopram on monoamine reuptake transporters. The serotonergic and noradrenergic actions of desvenlafaxine and duloxetine may provide for a faster onset of antidepressant activity in the elderly, but more definitive data are needed and the clinical effects of the possible faster onset of action need to be elucidated. Duloxetine and escitalopram are extensively metabolized via cytochrome P450 (CYP) enzymes and the decreased hepatic metabolism present in many older adults should be taken into account when prescribing these medications. Duloxetine possesses the greatest likelihood of producing clinically relevant drug-drug interactions because of its inhibition of CYP2D6. All three agents must also be used cautiously in older adults with poor renal function. In terms of clinical efficacy, 14 prospective published trials involving escitalopram (n = 8) and duloxetine (n = 6) in the treatment of older adults with major depressive disorder were identified. No such studies involving desvenlafaxine were found. Of the five randomized, double-blind, controlled trials, 46% and 37% of antidepressant-treated patients were considered responders and remitters, respectively. In contrast to escitalopram, duloxetine-treated patients experienced improvements in depressive symptoms that more consistently differentiated themselves from the symptoms of placebo-treated patients. Escitalopram and duloxetine were generally well tolerated, but 5–20% and 10–27% of patients, respectively, dropped out because of medication-related adverse effects. Adverse effects experienced by older adults were generally similar to those experienced by younger adults, although indirect comparisons suggest that older adults are more likely to experience dry mouth and constipation with duloxetine and escitalopram, while orthostasis may be more common in older adults prescribed desvenlafaxine. Overall, duloxetine and escitalopram represent modestly effective treatments for late-life depression that are generally well tolerated but do produce a variety of adverse effects. Conclusions regarding desvenlafaxine cannot be made at this time because of a lack of geriatric-specific data.

Notes

Acknowledgements

The authors have no actual or potential conflicts of interest that are directly relevant to the content of this review. No sources of funding were used to assist in the completion of this review; the authors completed all aspects of the manuscript as part of their regular employment.

References

  1. 1.
    Blazer D, Hughes DC, George LK. The epidemiology of depression in an elderly community population. Gerontologist 1987 Jun; 27(3): 281–7PubMedCrossRefGoogle Scholar
  2. 2.
    Koenig H, Blazer D. Mood disorders. In: Blazer D, Steffens D, Busse E, editors. Textbook of geriatric psychiatry. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc., 2004: 241–68Google Scholar
  3. 3.
    Covinsky KE, Kahana E, Chin MH, et al. Depressive symptoms and 3-year mortality in older hospitalized medical patients. Ann Intern Med 1999 Apr 6; 130(7): 563–9PubMedGoogle Scholar
  4. 4.
    Dunham NC, Sager MA. Functional status, symptoms of depression, and the outcomes of hospitalization in community-dwelling elderly patients. Arch Fam Med 1994 Aug; 3(8): 676–80; discussion 81PubMedCrossRefGoogle Scholar
  5. 5.
    Inouye SK, Peduzzi PN, Robison JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998 Apr 15; 279(15): 1187–93PubMedCrossRefGoogle Scholar
  6. 6.
    Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006 May; 113(5): 372–87PubMedCrossRefGoogle Scholar
  7. 7.
    Jongenelis K, Pot AM, Eisses AM, et al. Prevalence and risk indicators of depression in elderly nursing home patients: the AGED study. J Affect Disord 2004 Dec; 83(2–3): 135–42PubMedCrossRefGoogle Scholar
  8. 8.
    Small GW. Recognition and treatment ofdepression in the elderly. J Clin Psychiatry 1991 Jun; Suppl. 52: 11–22Google Scholar
  9. 9.
    Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry 2005 Sep; 162(9): 1588–601PubMedCrossRefGoogle Scholar
  10. 10.
    Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008 Jul; 16(7): 558–67PubMedCrossRefGoogle Scholar
  11. 11.
    Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single-versus dual-action antidepressants. Clin Ther 2009 May; 31(5): 945–61PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor WD, Doraiswamy PM. A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. Neuropsychopharmacology 2004 Dec; 29(12): 2285–99PubMedCrossRefGoogle Scholar
  13. 13.
    Daws LC. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 2009; 121(1): 89–99PubMedCrossRefGoogle Scholar
  14. 14.
    Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001 Dec; 25(6): 871–80PubMedCrossRefGoogle Scholar
  15. 15.
    Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006 Aug; 318(2): 657–65PubMedCrossRefGoogle Scholar
  16. 16.
    Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50(5): 345–50PubMedCrossRefGoogle Scholar
  17. 17.
    Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exper Ther 1997 Dec; 283(3): 1305–22Google Scholar
  18. 18.
    Yang LP, Plosker GL. Desvenlafaxine extended release. CNS Drugs 2008; 22(12): 1061–9PubMedCrossRefGoogle Scholar
  19. 19.
    Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 2003 Sep; 28(9): 1685–93PubMedCrossRefGoogle Scholar
  20. 20.
    Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11(12): 1475–93PubMedCrossRefGoogle Scholar
  21. 21.
    Alfinito PD, Huselton C, Chen X, et al. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 2006; 1098(1): 71–8PubMedCrossRefGoogle Scholar
  22. 22.
    Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 Jul; 56(7): 1333–41PubMedCrossRefGoogle Scholar
  23. 23.
    Plenge P, Gether U, Rasmussen SG. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 2007 Jul 12; 567(1–2): 1–9PubMedCrossRefGoogle Scholar
  24. 24.
    Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003 Aug; 45(2): 167–73PubMedCrossRefGoogle Scholar
  25. 25.
    Sanchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004 Jul; 174(2): 163–76PubMedCrossRefGoogle Scholar
  26. 26.
    Sanchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004 Feb; 77(2): 391–8PubMedCrossRefGoogle Scholar
  27. 27.
    Stahl SM. Stahl’s essential psychopharmacology. 3rd ed. New York: Cambridge University Press, 2008Google Scholar
  28. 28.
    Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001; 62Suppl. 15: 12–7PubMedGoogle Scholar
  29. 29.
    Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002 Winter; 8(4): 361–76PubMedCrossRefGoogle Scholar
  30. 30.
    Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001; 62Suppl. 4: 17–23; discussion 37-40PubMedGoogle Scholar
  31. 31.
    Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10(5): 541–50PubMedGoogle Scholar
  32. 32.
    Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004 Feb 1; 55(3): 296–300PubMedCrossRefGoogle Scholar
  33. 33.
    Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992 Oct; 161: 562–5PubMedCrossRefGoogle Scholar
  34. 34.
    Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989 Dec; 50(12): 447–9PubMedGoogle Scholar
  35. 35.
    Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46(4): 281–90PubMedCrossRefGoogle Scholar
  36. 36.
    Pristiq® (desvenlafaxine) [US prescribing information]. Philadelphia (PA): Wyeth Pharmaceuticals, 2009Google Scholar
  37. 37.
    Cymbalta® (duloxetine hydrochloride) [US prescribing information]. Indianapolis (IN): Eli Lilly, 2009Google Scholar
  38. 38.
    Lexapro® (escitalopram oxalate) [US prescribing information]. St. Louis (MO): Forest Pharmaceuticals, 2009Google Scholar
  39. 39.
    Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003 Sep 1; 31(9): 1142–50PubMedCrossRefGoogle Scholar
  40. 40.
    Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000 Feb; 40(2): 161–7PubMedCrossRefGoogle Scholar
  41. 41.
    Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57(5): 540–4PubMedCrossRefGoogle Scholar
  42. 42.
    Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2(4): 274–302PubMedCrossRefGoogle Scholar
  43. 43.
    Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res 2001; 15(6): 897–918CrossRefGoogle Scholar
  44. 44.
    Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38(8): 843–53PubMedCrossRefGoogle Scholar
  45. 45.
    Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003 Mar; 73(3): 170–7PubMedCrossRefGoogle Scholar
  46. 46.
    Suri A, Reddy S, Gonzales C, et al. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther 2005 Feb; 43(2): 78–84PubMedGoogle Scholar
  47. 47.
    Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007 Apr; 41(4): 674–80PubMedCrossRefGoogle Scholar
  48. 48.
    Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007 Feb; 27(1): 28–34PubMedCrossRefGoogle Scholar
  49. 49.
    Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008 Jul; 30(7): 1206–27PubMedCrossRefGoogle Scholar
  50. 50.
    Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39PubMedCrossRefGoogle Scholar
  51. 51.
    Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47(3): 191–202PubMedCrossRefGoogle Scholar
  52. 52.
    von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 Aug; 29(8): 1102–9Google Scholar
  53. 53.
    Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009 Feb; 49(2): 219–28PubMedCrossRefGoogle Scholar
  54. 54.
    Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008 Dec; 36(12): 2484–91PubMedCrossRefGoogle Scholar
  55. 55.
    Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005 Oct; 13(10): 884–91PubMedGoogle Scholar
  56. 56.
    Kasper S, Lemming OM, de Swart H. Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology 2006; 54(3): 152–9PubMedCrossRefGoogle Scholar
  57. 57.
    Mohamed S, Osatuke K, Aslam M, et al. Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother 2006 Sep; 4(3): 201–9PubMedCrossRefGoogle Scholar
  58. 58.
    Rao V, Spiro JR, Rosenberg PB, et al. An open-label study of escitalopram (Lexapro) for the treatment of ‘depression of Alzheimer’s disease’ (dAD). Int J Geriatr Psychiatry 2006 Mar; 21(3): 273–4PubMedCrossRefGoogle Scholar
  59. 59.
    Weintraub D, Taraborelli D, Morales KH, et al. Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006 Summer; 18(3): 377–83PubMedCrossRefGoogle Scholar
  60. 60.
    Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007 Jul; 15(7): 581–93PubMedCrossRefGoogle Scholar
  61. 61.
    Saghafi R, Brown C, Butters MA, et al. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. Int J Geriatr Psychiatry 2007 Nov; 22(11): 1141–6PubMedCrossRefGoogle Scholar
  62. 62.
    Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008 Jan; 16(1): 14–20PubMedCrossRefGoogle Scholar
  63. 63.
    Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004 Dec 7; 4: 11PubMedCrossRefGoogle Scholar
  64. 64.
    Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005 Mar; 13(3): 227–35PubMedGoogle Scholar
  65. 65.
    Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007 Jun; 164(6): 900–9PubMedCrossRefGoogle Scholar
  66. 66.
    Karp JF, Whyte EM, Lenze EJ, et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. J Clin Psychiatry 2008 Mar; 69(3): 457–63PubMedCrossRefGoogle Scholar
  67. 67.
    Karp JF, Weiner DK, Dew MA, et al. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study. Int J Geriatr Psychiatry 2010 Jun; 25(6): 633–42PubMedGoogle Scholar
  68. 68.
    Wohlreich MM, Sullivan MD, Mallinckrodt CH, et al. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis. Psychosomatics 2009 Jul-Aug; 50(4): 402–12PubMedCrossRefGoogle Scholar
  69. 69.
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 Apr; 134: 382–9PubMedCrossRefGoogle Scholar
  70. 70.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 Feb; 23: 56–62PubMedCrossRefGoogle Scholar
  71. 71.
    Kok RM, Nolen WA, Heeren TJ. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial. Int J Geriatr Psychiatry 2007 Dec; 22(12): 1247–54PubMedCrossRefGoogle Scholar
  72. 72.
    Mazeh D, Shahal B, Aviv A, et al. A randomized, singleblind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007 Nov; 22(6): 371–5PubMedCrossRefGoogle Scholar
  73. 73.
    Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006 Apr; 14(4): 361–70PubMedCrossRefGoogle Scholar
  74. 74.
    Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004 Dec; 19(12): 1123–30PubMedCrossRefGoogle Scholar
  75. 75.
    Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008 Apr 30; 23(6): 850–7PubMedCrossRefGoogle Scholar
  76. 76.
    de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 2007; 24(1): 36–41PubMedCrossRefGoogle Scholar
  77. 77.
    Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163(9): 1519–30; quiz 665PubMedCrossRefGoogle Scholar
  78. 78.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1231–42PubMedCrossRefGoogle Scholar
  79. 79.
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1243–52PubMedCrossRefGoogle Scholar
  80. 80.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006 Jan; 163(1): 28–40PubMedCrossRefGoogle Scholar
  81. 81.
    Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 2009; 26(5): 381–94PubMedCrossRefGoogle Scholar
  82. 82.
    Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9(1): 47–59PubMedGoogle Scholar
  83. 83.
    Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004 Nov 22; 164(21): 2367–70PubMedCrossRefGoogle Scholar
  84. 84.
    Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008 Jan 28; 168(2): 180–5PubMedCrossRefGoogle Scholar
  85. 85.
    Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006 Feb; 119(2): 113–6PubMedCrossRefGoogle Scholar
  86. 86.
    Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 2008 Apr-Jun; 8(2): 133–45PubMedGoogle Scholar
  87. 87.
    Warden SJ, Haney EM. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact 2008 Apr-Jun; 8(2): 121–32PubMedGoogle Scholar
  88. 88.
    Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007 Aug 23; 357(8): 762–74PubMedCrossRefGoogle Scholar
  89. 89.
    Camacho ME, Reyes-Ortiz CA. Sexual dysfunction in the elderly: age or disease? Int J Impot Res 2005 Dec; 17Suppl. 1: S52–6PubMedCrossRefGoogle Scholar
  90. 90.
    Moreira Jr ED, Hartmann U, Glasser DB, et al. A population survey of sexual activity, sexual dysfunction and associated help-seeking behavior in middle-aged and older adults in Germany. Eur J Med Res 2005 Oct 18; 10(10): 434–43PubMedGoogle Scholar
  91. 91.
    Korfage IJ, Pluijm S, Roobol M, et al. Erectile dysfunction and mental health in a general population of older men. J Sex Med 2009 Feb; 6(2): 505–12PubMedCrossRefGoogle Scholar
  92. 92.
    Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr 2006 Aug; 11(8 Suppl. 9): 19–23PubMedGoogle Scholar
  93. 93.
    Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006; 67Suppl. 6: 33–7PubMedGoogle Scholar
  94. 94.
    Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009 Apr; 29(2): 157–64PubMedCrossRefGoogle Scholar
  95. 95.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Publishing, Inc.,2000Google Scholar
  96. 96.
    Lebret S, Perret-Vaille E, Mulliez A, et al. Elderly suicide attempters: characteristics and outcome. Int J Geriatr Psychiatry 2006 Nov; 21(11): 1052–9PubMedCrossRefGoogle Scholar
  97. 97.
    Waern M, Rubenowitz E, Runeson B, et al. Burden of illness and suicide in elderly people: case-control study [letter]. BMJ 2002 Jun 8; 324(7350): 1355PubMedCrossRefGoogle Scholar
  98. 98.
    Suominen K, Isometsa E, Lonnqvist J. Elderly suicide attempters with depression are often diagnosed only after the attempt. Int J Geriatr Psychiatry 2004 Jan; 19(1):35–40PubMedCrossRefGoogle Scholar
  99. 99.
    Nelson JC, Delucchi K, Schneider L. Suicidal thinking and behavior during treatment with sertraline in late-life depression. Am J Geriatr Psychiatry 2007 Jul; 15(7): 573–80PubMedCrossRefGoogle Scholar
  100. 100.
    Food and Drug Administration. Psychopharmacologic Drug Advisory Committee transcript from December 13, 2006 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4272t1-part1.pdf [Accessed 2010 Mar 2]
  101. 101.
    Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk ofsuicide: a systematic review of observational studies. Can Med Assoc J 2009 Feb 3; 180(3): 291–7CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Christian Dolder
    • 1
    • 2
  • Michael Nelson
    • 3
  • Andrea Stump
    • 1
  1. 1.Wingate University School of PharmacyWingateUSA
  2. 2.Carolinas Medical Center, NorthEastConcordUSA
  3. 3.Rueckert-Hartman College for Health Professions School of PharmacyRegis UniversityDenverUSA

Personalised recommendations